BICO Group AB
STO:BICO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BICO Group AB
Income from Continuing Operations
BICO Group AB
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BICO Group AB
STO:BICO
|
Income from Continuing Operations
-kr1.6B
|
CAGR 3-Years
-162%
|
CAGR 5-Years
-100%
|
CAGR 10-Years
N/A
|
|
|
AddLife AB
STO:ALIF B
|
Income from Continuing Operations
kr562m
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
A
|
AroCell AB (publ)
STO:AROC
|
Income from Continuing Operations
-kr12.2m
|
CAGR 3-Years
41%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-5%
|
|
|
Biotage AB
STO:BIOT
|
Income from Continuing Operations
kr255m
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
G
|
Genovis AB
STO:GENO
|
Income from Continuing Operations
kr23.5m
|
CAGR 3-Years
28%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
MedCap AB (publ)
STO:MCAP
|
Income from Continuing Operations
kr220.7m
|
CAGR 3-Years
23%
|
CAGR 5-Years
28%
|
CAGR 10-Years
35%
|
|
BICO Group AB
Glance View
BICO Group AB is a bioconvergence company, which engages in the provision of technologies, products, and services to create, understand and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 890 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
See Also
What is BICO Group AB's Income from Continuing Operations?
Income from Continuing Operations
-1.6B
SEK
Based on the financial report for Dec 31, 2025, BICO Group AB's Income from Continuing Operations amounts to -1.6B SEK.
What is BICO Group AB's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-100%
Over the last year, the Income from Continuing Operations growth was -1 340%. The average annual Income from Continuing Operations growth rates for BICO Group AB have been -162% over the past three years , -100% over the past five years .
